The rise in the popularity of weight loss injections has been one of the most remarkable developments in healthcare over the past few years, and 2024 has only amplified this trend. At the Tracey Bell Clinic, we’ve seen more patients than ever exploring these innovative treatments to help them achieve their weight loss goals.
The most common question I hear is: “Which pen should I use?” The two most popular options are Wegovy and
Mounjaro. Both are highly effective tools for weight loss, but they work differently, and choosing the right one requires a thorough understanding of what each offers.
Let’s dive deeper into the details of these treatments, how they work, their development, and the risks and benefits associated with each.
What Is Wegovy?
Wegovy, a brand name for semaglutide, is a medication that belongs to a class of drugs known as GLP-1 receptor agonists. It was initially developed by Novo Nordisk and approved by the FDA in June 2021 as a treatment specifically for chronic weight management. Its development builds on the success of Ozempic, another semaglutide medication used for managing type 2 diabetes.
In the UK, Wegovy was introduced for weight loss in September 2023 under very specific guidelines about who could provide it and how it could be administered. These guidelines are designed to ensure that the treatment is offered safely and appropriately, with proper medical oversight.
How Does Wegovy Work?
Wegovy works by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone your body naturally produces in response to eating. GLP-1:
Reduces appetite by signaling the brain to feel full sooner
Slows gastric emptying, which keeps food in the stomach longer and helps you feel fuller for longer
Regulates blood sugar levels by influencing insulin production
This combination makes Wegovy a powerful tool for weight loss, particularly when used alongside a healthy diet and regular exercise.
Who Is Wegovy For?
Wegovy is prescribed for adults with:
A BMI of 30 or higher (classified as obese)
A BMI of 27 or higher (classified as overweight) if they have at least one weight-related medical condition, such as type 2 diabetes, hypertension, or high cholesterol
Expected Benefits of Wegovy
Clinical trials have shown that Wegovy can help individuals lose up to 15% of their body weight when used consistently. This makes it a highly effective option for those looking for moderate weight loss results.
What Is Mounjaro?
Mounjaro, the brand name for tirzepatide, is a relatively new medication developed by Eli Lilly. It was first approved by the FDA in May 2022 for managing type 2 diabetes. Although not yet officially approved solely for weight loss, Mounjaro has been shown to offer significant weight loss benefits and is frequently prescribed off-label for this purpose.
How Does Mounjaro Work?
Unlike Wegovy, which targets only GLP-1, Mounjaro is a dual-action treatment. It activates both:
GLP-1 receptors, helping regulate appetite and blood sugar
GIP (glucose-dependent insulinotropic polypeptide) receptors, enhancing the body’s ability to manage blood sugar and possibly amplifying weight loss
This dual mechanism makes Mounjaro particularly effective for those with more significant weight loss goals or additional metabolic challenges.
Who Is Mounjaro For?
Mounjaro is currently approved for individuals with type 2 diabetes but is increasingly prescribed for weight loss in patients with:
A higher BMI or more substantial weight loss needs
Weight-related health conditions, including insulin resistance or metabolic syndrome
Expected Benefits of Mounjaro
At the Tracey Bell Clinic, every weight loss plan is rooted in evidence-based medicine. When we discuss options like Wegovy and Mounjaro, we take the time to share the latest clinical research and explain how it applies to your unique situation.
Clinical Evidence: Wegovy
Wegovy has been studied extensively, with clinical trials showing an average weight loss of 15% of body weight over 68 weeks
It is most effective when combined with a calorie-controlled diet and increased physical activity
Evidence highlights that it can improve markers of metabolic health, such as lowering blood sugar levels and reducing the risk of cardiovascular disease
Clinical Evidence: Mounjaro
Mounjaro’s dual action has been shown to result in 20% or more weight loss for some patients, with studies indicating it may outperform GLP-1-only medications like Wegovy in certain scenarios
Clinical trials also highlight its effectiveness in improving insulin sensitivity and managing type 2 diabetes alongside weight loss
Understanding Risks and Benefits
In every consultation, we discuss both the potential benefits and risks. We explain the side effects, which can range from nausea and digestive upset to rarer issues like pancreatitis or gallbladder problems. It’s also important to talk about realistic expectations—these treatments work, but they are not quick fixes.
Tailored to You
The decision to use Wegovy or Mounjaro is ultimately yours, but it’s informed by our clinical expertise. Together, we’ll evaluate:
Your BMI and overall health profile
How much weight you need to lose and your personal goals
Any pre-existing conditions, like type 2 diabetes or heart disease
We also ensure that you understand the lifestyle changes required to support these treatments. Success isn’t just about the pen—it’s about the holistic plan we create together.
Access to Wegovy and Mounjaro on the Isle of Man
One key challenge for patients on the Isle of Man is access to these medications. At present:
Wegovy is not available on the NHS on the Isle of Man, only privately
Mounjaro, while available privately, is also not provided on the NHS on the Isle of Man
This means that patients seeking these treatments must go through private clinics, like the Tracey Bell Clinic, where we ensure the highest standards of care and personalised guidance.
Key Differences Between Wegovy and Mounjaro
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
| Main Ingredient | Semaglutide | Tirzerpatide |
| Mechanism | GLP-1 agonist | Dual GLP-1 GIP agonist |
| Eligibility | BMI≥ (or ≥ 27 with conditions | Higher BMI, often type 2 diabetes |
| Expected weight loss | ~15% body weight | ~20% body weight |
Conclusion
At the Tracey Bell Clinic, our goal is to empower you with knowledge and provide evidence-based, personalised care. Both Wegovy and Mounjaro are excellent tools, but they’re just that—tools. The real transformation happens when these treatments are combined with a commitment to healthy eating, regular exercise, and long-term lifestyle changes.
If you’re considering weight loss injections and wondering which is right for you, book a consultation with us today. Together, we’ll explore your options and set you on a path to success.